Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase in... Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of patients with uncontrolled or resistant hypertension. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania. Show more
RADNOR, Pa., June 14, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.09 | -0.664697193501 | 13.54 | 14.07 | 13.1 | 374202 | 13.64602657 | CS |
4 | 1.81 | 15.5498281787 | 11.64 | 15.12 | 11.09 | 331679 | 12.98174981 | CS |
12 | -0.14 | -1.03016924209 | 13.59 | 15.12 | 11.04 | 225158 | 12.89594315 | CS |
26 | 2.73 | 25.4664179104 | 10.72 | 16.905 | 9.78 | 195156 | 13.14521176 | CS |
52 | -1.28 | -8.68974881195 | 14.73 | 16.905 | 5.85 | 187567 | 11.55097114 | CS |
156 | -7.65 | -36.2559241706 | 21.1 | 21.98 | 5.85 | 190810 | 12.99241399 | CS |
260 | -7.65 | -36.2559241706 | 21.1 | 21.98 | 5.85 | 190810 | 12.99241399 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.